Teacher Retirement System of Texas lowered its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 90.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,753 shares of the medical research company's stock after selling 101,572 shares during the period. Teacher Retirement System of Texas' holdings in IQVIA were worth $2,113,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of IQV. FMR LLC increased its stake in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock valued at $684,213,000 after acquiring an additional 804,963 shares during the period. Cantillon Capital Management LLC grew its stake in shares of IQVIA by 12.3% in the 4th quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company's stock valued at $406,018,000 after purchasing an additional 226,017 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after buying an additional 583,396 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock worth $277,908,000 after buying an additional 452,029 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its stake in IQVIA by 3.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,890 shares of the medical research company's stock valued at $245,026,000 after buying an additional 44,991 shares in the last quarter. Institutional investors own 89.62% of the company's stock.
Analyst Upgrades and Downgrades
IQV has been the subject of a number of analyst reports. UBS Group cut their price objective on IQVIA from $260.00 to $255.00 and set a "buy" rating for the company in a report on Friday, February 7th. Citigroup cut their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. William Blair reaffirmed an "outperform" rating on shares of IQVIA in a research note on Wednesday, December 11th. Barclays cut their target price on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd. Finally, Bank of America decreased their price target on IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA currently has an average rating of "Moderate Buy" and an average target price of $249.05.
Check Out Our Latest Analysis on IQVIA
IQVIA Trading Down 1.2 %
NYSE IQV traded down $2.10 during trading hours on Friday, hitting $177.27. The company's stock had a trading volume of 1,583,083 shares, compared to its average volume of 1,299,295. IQVIA Holdings Inc. has a twelve month low of $176.03 and a twelve month high of $253.84. The firm has a market capitalization of $31.25 billion, a P/E ratio of 23.64, a PEG ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a fifty day moving average of $193.15 and a 200 day moving average of $206.05.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
